Fig. 6 | Signal Transduction and Targeted Therapy

Fig. 6

From: A first-in-class selective inhibitor of ERK1/2 and ERK5 overcomes drug resistance with a single-molecule strategy

Fig. 6

SKLB-D18 induced ferritinophagy in MDA-MB-231 and MDA-MB-468 cells. a Flow cytometry was used to evaluate the ROS levels after treatment of SKLB-D18 (5 μM) and combination of BVD-523 (5 μM) and XMD9-82 (5 μM). b MDA levels were detected after 24 h treatment of SKLB-D18 (1, 2.5, 5 μM) and combination of BVD-523 (5 μM) and XMD9-82 (5 μM). c Immunofluorescence analysis of free ferrous ions levels by FerroOrange probe after 24 h treatment of SKLB-D18 (1, 2.5, 5 μM) and combination of BVD-523 (5 μM) and XMD9-82 (5 μM). d Immunoblotting analysis of protein levels of NCOA4, GPX4, p62 and LC3I/II following treatment with SKLB-D18 (5 μM) and combination of BVD-523 (5 μM) and XMD9-82 (5 μM) for 24 h. e Immunoblotting analysis of protein levels of NCOA4, p62 and LC3I/II after 24 h co-incubation of SKLB-D18 (5 μM) and CQ (1 μM). f Flow cytometry was used to evaluate the ROS levels after 24 h co-incubation of SKLB-D18 (5 μM) and CQ (1 μM). g MDA levels were detected after 24 h co-incubation of SKLB-D18 (5 μM) and CQ (10 μM). h Immunofluorescence analysis of free ferrous ions levels by FerroOrange probe after 24 h co-incubation of SKLB-D18 (5 μM) and CQ (1 μM). Scale bar, 100 μm. Data are presented as Mean ± SD. Compared to the Control group: ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. Compared to the SKLB-D18 treatment group: #p < 0.05, ##p < 0.01, ###p < 0.001

Back to article page